Clearmind Medicine Advances CMND-100 Into AUD Clinical Trial
VANCOUVER, Canada — September 11, 2026 Clearmind Medicine Inc. announced that the first patients with Alcohol Use Disorder (AUD)...
neuroplastogen
Advertisement
Persica Strengthens PP353 Case in Vertebrogenic Back Pain
London, UK — September 4, 2026 Persica Pharmaceuticals Limited announced the publication of new antibiotic exposure-response analyses supporting the...
Clearmind Advances CMND-100 Into Phase IIa Trial for Alcohol Use Disorder
Vancouver, Canada — September 1, 2026 Clearmind Medicine Inc. announced the initiation of Phase IIa development for CMND-100, its...
Clearmind Reports Positive Intranasal MEAI Results
Vancouver, Canada, July 16, 2026 Clearmind Medicine announced positive ex vivo results demonstrating enhanced nasal retention for its intranasal...
DemeRx Gains FDA IND Clearance for DMX-1001 in AUD
Miami, Florida, USA – April 23, 2026 DemeRx announced that the U.S. Food and Drug Administration (FDA) has accepted...
Advertisement
